Prostate cancer and the Mevalonate pathway

Guerrero-Ochoa, Patricia ; Rodríguez-Zapater, Sergio (Universidad de Zaragoza) ; Anel, Alberto (Universidad de Zaragoza) ; Esteban, Luis Mariano ; Camón-Fernández, Alejandro ; Espilez-Ortiz, Raquel ; Gil-Sanz, María Jesús (Universidad de Zaragoza) ; Borque-Fernando, Ángel (Universidad de Zaragoza)

Resumen: Antineoplastic therapies for prostate cancer (PCa) have traditionally centered around the androgen receptor (AR) pathway, which has demonstrated a significant role in oncogenesis. Nevertheless, it is becoming progressively apparent that therapeutic strategies must diversify their focus due to the emergence of resistance mechanisms that the tumor employs when subjected to monomolecular treatments. This review illustrates how the dysregulation of the lipid metabolic pathway constitutes a survival strategy adopted by tumors to evade eradication efforts. Integrating this aspect into oncological management could prove valuable in combating PCa.

Idioma: Inglés

DOI: 10.3390/ijms25042152

Año: 2024

Publicado en: International Journal of Molecular Sciences 25, 4 (2024), 2152 [21 pp.]
ISSN: 1661-6596

Financiación: info:eu-repo/grantAgreement/ES/DGA/T69-23R

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Área Bioquímica y Biolog.Mole. (Dpto. Bioq.Biolog.Mol. Celular)
Área (Departamento): Área Medicina y Cirugía Animal (Dpto. Patología Animal)
Área (Departamento): Área Urología (Dpto. Cirugía)